Corcept Therapeutics Target Price

See Corcept Therapeutics's analyst price targets ($130) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$79.22

Average Target Price

$132.25

66.9% upside

4 analysts in the last 4 months

High: $165 | Low: $50

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-18	Truist FinancialSrikripa Devarakonda	$164	107% upside
2026-07-30	H.C. WainwrightSwayampakula Ramakanth	$165	108.3% upside
2026-07-29	Canaccord GenuityEdward Nash	$150	89.3% upside
2026-07-27	Wolfe Research	$50	36.9% downside
2026-06-02	H.C. WainwrightSwayampakula Ramakanth	$95	19.9% upside
2026-05-28	UBS	$135	70.4% upside
2026-05-13	UBS	$72	9.1% downside
2026-05-04	H.C. Wainwright	$75	5.3% downside
2026-05-01	Piper Sandler	$88	11.1% upside
2026-02-20	H.C. Wainwright	$67	15.4% downside
2026-01-23	Canaccord Genuity	$100	26.2% upside
2026-01-22	H.C. WainwrightSwayampakula Ramakanth	$105	32.5% upside
2026-01-02	H.C. WainwrightSwayampakula Ramakanth	$90	13.6% upside
2026-01-02	Canaccord GenuityEdward Nash	$99	25% upside
2025-12-31	Truist Financial	$50	36.9% downside
2025-12-31	Wolfe Research	$30	62.1% downside
2025-12-16	UBSAshwani Verma	$95	19.9% upside
2025-09-10	Canaccord Genuity	$140	76.7% upside
2025-05-06	Truist FinancialJoon Lee	$135	70.4% upside
2025-05-06	H.C. WainwrightSwayampakula Ramakanth	$145	83% upside
2024-10-18	H.C. WainwrightSwayampakula Ramakanth	$80	1% upside
2024-09-30	Truist FinancialJoon Lee	$76	4.1% downside
2024-08-15	Canaccord GenuityEdward Nash	$78	1.5% downside
2024-07-30	Piper SandlerDavid Amsellem	$38	52% downside
2024-07-30	H.C. WainwrightSwayampakula Ramakanth	$45	43.2% downside
2024-06-12	Canaccord GenuityEdward Nash	$38	52% downside
2024-06-10	Piper SandlerDavid Amsellem	$35	55.8% downside
2024-06-04	Truist FinancialJoon Lee	$65	18% downside
2024-05-02	H.C. WainwrightSwayampakula Ramakanth	$40	49.5% downside
2022-12-09	H.C. Wainwright	$30	62.1% downside
2022-08-04	H.C. Wainwright	$33	58.3% downside

Corcept Therapeutics (CORT) FAQ

The latest target price for CORT is $130. Investors often review this figure alongside Corcept Therapeutics's historical trend and sector peers before judging valuation or financial health.

Corcept Therapeutics trades near $79.22 while the consensus target sits at $130 (66.9% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting CORT's target price ($130), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Corcept Therapeutics's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.